PCaP Datasets – Definition/Algorithm (2010)

Dataset #1: Balanced by Race, State, and Aggressiveness

Previously - Phase I dataset

N=200 subjects

- > Includes post-Katrina, LA and NC subjects only
- ➤ 50 subjects in each state-race category comprised of 25 high and 25 low aggressive prostate cancer subjects
- > Diagnosis date after 07/01/2004
- > PCaP in-home visit completed
- ➤ Blood collected during PCaP in-home visit
- ➤ 8 or more Red Top serum aliquots
- ➤ 6 or more Yellow Top (EDTA) plasma aliquots
- ➤ 1 urine tube with preservative (crystalline ascorbic acid) and 1 tube without preservative
- > 3 or more 100ul iDNA (DNA extracted from immortalized cell lines) aliquots with 100ng/ul
- > Aggressiveness classification not missing
- Subject consented to other research use of samples including prostate cancer research (Note: this entire set can be used for any type of research)
- ➤ Not missing prostate-specific antigen (PSA)
- ➤ Not missing Gleason sum (Gleason sum or Gleason score = Primary Gleason Grade (grade 1-5 assigned to most common tumor pattern) + Secondary Gleason Grade (grade 1-5 assigned to second most common tumor pattern)
- ➤ Not missing clinical stage

Dataset #2: Radical Prostatectomy (RP)

Previously - Phase II dataset

N=200 subjects

- ➤ Includes NC subjects only
- > 100 AA and 100 CA
- > Subjects must have radical prostatectomy tissue on PCaP tissue microarrays # 1-5
- Diagnosis date after 07/01/2004
- > PCaP in-home visit completed
- ➤ Blood collected during PCaP in-home visit
- ➤ 8 or more Red Top serum aliquots
- ➤ 6 or more Yellow Top (EDTA) plasma aliquots
- ➤ 1 urine tube with preservative (crystalline ascorbic acid) and 1 tube without preservative
- > Aggressiveness classification not missing
- > Subject consented to other research or prostate cancer only future sample use (Note: this entire set can be used for prostate cancer research only even though some subjects in this set may have consented to future use for other research)
- ➤ Not missing prostate-specific antigen (PSA)
- ➤ Not missing Gleason sum (Gleason sum or Gleason score = Primary Gleason Grade (grade 1-5 assigned to most common tumor pattern) + Secondary Gleason Grade (grad 1-5 assigned to second most common tumor pattern)
- > Not missing clinical stage

Dataset #3: Untreated (self-report)

Previously - Phase III dataset

N=251 subjects

- ➤ Includes pre-K, post-K, LA and NC subjects
- All subjects must be <u>untreated</u> based on the self-reported questionnaire variable, i.e. untxdQx = 1 (UnTxd prior to the PCaP visit)
- ➤ Diagnosis date after 07/01/2004
- > PCaP in-home visit completed
- ➤ Blood collected during PCaP in-home visit
- ➤ 8 or more Red Top serum aliquots
- ➤ 6 or more Yellow Top (EDTA) plasma aliquots
- ➤ 1 urine tube with preservative (crystalline ascorbic acid) and 1 tube without preservative
- > 3 or more 100ul iDNA (DNA extracted from immortalized cell lines) aliquots with 100ng/ul
- > Aggressiveness classification not missing
- Consented to other or CaP only future sample use (<u>Note</u>: this entire set can be used for prostate cancer research only – even though some subjects in this set may have consented to future use for other research)
- ➤ Not missing prostate-specific antigen (PSA)
- ➤ Not missing Gleason sum (Gleason sum or Gleason score = Primary Gleason Grade (grade 1-5 assigned to most common tumor pattern) + Secondary Gleason Grade (grad 1-5 assigned to second most common tumor pattern)
- ➤ Not missing clinical stage

Dataset #4: Feasibility

Previously - Phase IV dataset

N=200 subjects

- > Includes post-K, LA and NC subjects only
- ➤ Should not overlap at all with Phase I, II or III
- ➤ Should be a random selection of PCaP subjects (will likely create the 50:30:20 distribution of low to high CaP aggressiveness given the random selection)
- ➤ Diagnosis date after 07/01/2004
- > PCaP in-home visit completed
- ➤ Blood collected during PCaP in-home visit
- ➤ 8 or more Red Top serum aliquots
- ➤ 6 or more Yellow Top (EDTA) plasma aliquots
- ➤ 1 urine tube with preservative (crystalline ascorbic acid) and 1 tube without preservative
- > 3 or more 100ul iDNA (DNA extracted from immortalized cell lines) aliquots with 100ng/ul
- ➤ Aggressiveness classification not missing
- Consented to other research use of samples including CaP (<u>Note</u>: this entire set can be used for any type of research)
- ➤ Not missing prostate-specific antigen (PSA)
- ➤ Not missing Gleason sum (Gleason sum or Gleason score = Primary Gleason Grade (grade 1-5 assigned to most common tumor pattern) + Secondary Gleason Grade (grad 1-5 assigned to second most common tumor pattern)
- > Not missing clinical stage

NOTE: For any serum request, accompanying data should include the variable regarding transport conditions (ambient or on ice) relevant only to UNC serum samples collected after 4/30/2007 (N=835 subjects).